

SUPPLEMENTARY TABLE 1. Data from Figure 2 in tabulated form. Mean values (SD) of Canada-Denmark spine total inflammation score and for vertebral body and posterior elements sub-scores. For comparison, change in SPARCC MRI spine index (23-DVU) is also shown. MRI scores were the average of the two readers, as observed.

Treatment group		Week 0	Week 6	Week 24	Week 48
		n _{adalimumab} =25	n _{adalimumab} =24	n _{adalimumab} =21	n _{adalimumab} =19
		n _{placebo} =24	n _{placebo} =23	n _{placebo} =21	n _{placebo} =20
CANDEN spine inflammation score	Adalimumab	10.2 (13)	4.5 (6.2)	3.3 (6.0)	2.3 (4.1)
	Placebo	7.3 (10)	6.5 (8.9)	3.4 (5.4)	4.0 (7.7)
- Vertebral body sub-score	Adalimumab	9.5 (12)	4.2 (5.9)	2.7 (4.9)	2.2 (4.0)
	Placebo	6.9 (9.9)	6.1 (8.4)	3.4 (5.3)	3.9 (7.7)
- Posterior elements sub-score	Adalimumab	0.7 (2.3)	0.2 (0.7)	0.5 (1.8)	0.1 (0.4)
	Placebo	0.4 (0.8)	0.4 (1.1)	0.0 (0.1)	0.0 (0.1)
SPARCC MRI spine index	Adalimumab	11.0 (14)	4.8 (6.4)	3.1 (5.8)	2.8 (4.5)
	Placebo	8.7 (13)	7.3 (10)	4.1 (6.7)	4.6 (9.9)

SUPPLEMENTARY TABLE 2. SPARCC developer scores*.

A. Mean (SD) of SPARCC MRI spine index (23-DVU)					
Treatment group		Week 0	Week 6	Week 24	Week 48
		n _{adalimumab} =25	n _{adalimumab} =24	n _{adalimumab} =21	n _{adalimumab} =19
		n _{placebo} =24	n _{placebo} =23	n _{placebo} =21	n _{placebo} =20
SPARCC MRI spine index*	Adalimumab	13.0 (14)	4.8 (6.3)	3.0 (5.6)	3.3 (5.7)
	Placebo	8.5 (11)	6.9 (9.8)	3.2 (4.6)	2.7 (4.8)
B. Baseline distribution and responsiveness of SPARCC MRI spine index					
	Observed range (mean; SD)	Median (IQR)	SRM at week 6	SRM at week 24	SRM at week 48
SPARCC MRI spine index*	0-42 (10.8; 13)	6 (2-13)	0.61	0.77	0.78
C. Change in scores from baseline to week 6 in adalimumab group compared with placebo group.					
	----- Adalimumab group -----		----- Placebo group -----		Difference in change score from baseline to week 6, p-value**
	Baseline (n=25)	Change at week 6 (n=24)	Baseline (n=24)	Change at week 6 (n=23)	
SPARCC MRI spine index*	13.0 (14)	-8.4 (11)	8.5 (11)	-1.9 (2.7)	0.02 / 0.005

*SPARCC developer scores, i.e. SPARCC scores by WM. SPARCC, Spondyloarthritis Research Consortium of Canada.

**Significance tests for difference in change scores at week 6 between groups were calculated by Mann Whitney-U tests with continuity correction / ANCOVA.